Wound healing composition of IGF-I and TGF-.beta. |
| We claim: 1. A method for healing an external wound of a mammal comprising applying to said wound a ... |
|
Flowable demineralized bone powder composition and its use in bone repair |
| What is claimed is: 1. A flowable composition for application to a bone defect site to promote new ... |
|
Crosslinkable polypeptide compositions |
| OF THE INVENTION In accordance with the present invention, there are provided chemically modified ... |
|
|
Comparative genomic hybridization (CGH)
| Details |
Inventors: Pinkel, Daniel; Gray, Joe W.; Kallioniemi, Anne; Kallioniemi, Olli-Pekka; Waldman, Frederic; Sakamoto, Masaru;
Assignee: The Regents of the University of California (Oakland, CA)
Primary Examiner: Jones; W. Gary
Assistant Examiner: Fredman; Jeffrey
Attorney, Agent or Firm: Burns, Doane, Swecker & Mathis, L.L.P.
Disclosed are new methods comprising the use, of in situ hybridization to detect abnormal nucleic acid sequence copy numbers in one or more genomes wherein repetitive sequences that bind to multiple loci in a reference chromosome spread are either substantially removed and/or their hybridization signals suppressed. The invention termed Comparative Genomic Hybridization (CGH) provides for methods of determining the relative number of copies of nucleic acid sequences in one or more subject genomes or portions thereof (for example, a tumor cell) as a function of the location of those sequences in a reference genome (for example, a normal human genome). The intensity(ies) of the signals from each labeled subject nucleic acid and/or the differences in the ratios between different signals from the labeled subject nucleic acid sequences are compared to determine the relative copy numbers of the nucleic acid sequences in the one or more subject genomes as a function of position along the reference chromosome spread. Amplifications, duplications and/or deletions in the subject genome(s) can be detected. Also provided is a method of determining the absolute copy numbers of substantially all RNA or DNA sequences in subject cell(s) or cell population(s). |
|
DETAILED DESCRIPTION Comparative Genomic Hybridization (CGH) has also been termed Copy Ratio Reverse Cytogenetics (CRRC), competition hybridization and quantitative in situ ratio karyotyping (QUIRK). Further, in the embodiment wherein fluorochromes are used as labels, it has been termed competition FISH (fluorescence in situ hybridization). CGH specifically provides methods whereby amplifications, duplications and/or deletions can be identified in an immediate overview of a genome. CGH provides methods for determining variations in the copy number of different elements in a mixture of nucleic acid sequences (for example, genomic DNA isolated from a tumor) as a function of the location of those sequences in the genome of a reference organism (for example, the genome of a normal cell from the same species). The methods comprise the use of in situ hybridization of the nucleic acid sequence mixture to a chromosome spread of the reference organism, and measuring the intensity of the hybridization at different locations along the target chromosomes. Exemplary methods are schematically outlined in FIGS. 2-7. Those illustrative examples are not exhaustive but suggest the wide range of variations and other uses of the basic approach. As the figure descriptions indicate, it is critical that signals from repetitive sequences do not dominate the signal from the subject nucleic acid pool, and that they be removed from the pool or that their signals be suppressed as necessary. It is preferred to exclude sequences from the hybridization or block sequences in the hybridization mixture that could bind to multiple clearly separated positions on the chromosomes, for example, sites that are on different chromosomes, or that are on the same chromosome but are well-separated. In many applications of CGH, it is the high copy repetitive sequences, such as Alu, Kpn, Lines, and alpha-satellites among others, that are removed from the labeled subject nucleic acid and/or which are blocked and/or the binding sites therefor are blocked
|
| Related patents |
|
|
DNA sequence-based HLA typing method
The present invention relates to a method for determining the nucleic acid sequence of one or more polymorphic genes of a subject by amplifying and direct sequencing ...
|
|
|
Alterations in the long QT syndrome genes KVLQT1 and SCN5A and methods for detecting same
OF THE INVENTION The present invention relates to alterations in the KVLQT1, HERG, SCN5A, KCNE1 and KCNE2 genes and methods for detecting such alterations. The ...
|
|
|
Method for forming image
OF THE INVENTION In accordance with the present invention there is provided a method for processing a silver halide color photographic material that has silver halide ...
|
|
|
WF11243 substance
We claim: 1. An isolated compound having formula (I): ##STR4## or a salt thereof. 2. A method for producing a compound of formula (I): ##STR5## or a salt thereof which ...
|
|
|
Plant virus vector, plasmid, process for expression of foreign gene and process for obtaining foreign gene product
The purpose of the present invention is to provide plant virus vectors having the ability to systemically infect a whole plant; plasmids, which are transcribed to ...
|
|
|
Electrophoretic method for the isolation and separation of microorganisms and cell populations
It is an object of the invention to provide a novel electrophoretic method for the separation of viable mixtures of viable bacteria for analysis of microbial communities....
|
|
|
Human antithrombin III
The present invention is directed to the means and methods of producting human antithrombin III via recombinant DNA technology, including (1) the discovery and identity ...
|
|
|
Cryptophycins
OF THE INVENTION The present invention provides novel cryptophycin compounds having the following structure: ##STR4## Wherein R.sub.1 is H, OH, a halogen, O of a ketone ...
|
|
|
Method for recovery of refined .alpha.-galactosidase
OF THE INVENTION The methods heretofore suggested for the refinement of .alpha.-galactosidase suffer from various disadvantages such as poor recovery ratio, ...
|
|
|
Antimicrobial composition containing Type II endoglycosidase and antimicrobial agent
The invention provides antimicrobial methods utilizing Type II endoglycosidases such as endo-.beta.-N-acetylglucosaminidase ("Endo") H, D, F and/or PNGase F alone or in ...
|
|
|